Unknown

Dataset Information

0

Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.


ABSTRACT:

Aim

To investigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes in a large multicentric study.

Materials and methods

This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs. non-users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW).

Results

Five hundred and ninety-six participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW-adjusted models showed no significant association between the use of DPP-4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77-1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death.

Conclusions

These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.

SUBMITTER: Roussel R 

PROVIDER: S-EPMC8013481 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.

Roussel Ronan R   Darmon Patrice P   Pichelin Matthieu M   Goronflot Thomas T   Abouleka Yawa Y   Ait Bachir Leila L   Allix Ingrid I   Ancelle Deborah D   Barraud Sara S   Bordier Lyse L   Carlier Aurélie A   Chevalier Nicolas N   Coffin-Boutreux Christine C   Cosson Emmanuel E   Dorange Anne A   Dupuy Olivier O   Fontaine Pierre P   Fremy Bénédicte B   Galtier Florence F   Germain Natacha N   Guedj Anne-Marie AM   Larger Etienne E   Laugier-Robiolle Stéphanie S   Laviolle Bruno B   Ludwig Lisa L   Monier Arnaud A   Montanier Nathanaëlle N   Moulin Philippe P   Moura Isabelle I   Prevost Gaëtan G   Reznik Yves Y   Sabbah Nadia N   Saulnier Pierre-Jean PJ   Serusclat Pierre P   Vatier Camille C   Wargny Matthieu M   Hadjadj Samy S   Gourdy Pierre P   Cariou Bertrand B  

Diabetes, obesity & metabolism 20210216 5


<h4>Aim</h4>To investigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes in a large multicentric study.<h4>Materials and methods</h4>This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilati  ...[more]

Similar Datasets

| S-EPMC10475964 | biostudies-literature
| S-EPMC8390252 | biostudies-literature
| S-EPMC10198893 | biostudies-literature
| S-EPMC6349276 | biostudies-literature
| S-EPMC9315378 | biostudies-literature
| S-EPMC10712048 | biostudies-literature
| S-EPMC8566991 | biostudies-literature
| S-EPMC9331841 | biostudies-literature
| S-EPMC3782406 | biostudies-other